GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma

INTRODUCTION: Lenvatinib has recently become available as the first-line therapy for advanced hepatocellular carcinoma (HCC), but its molecular mechanism in HCC remains largely unknown. OBJECTIVES: The current study aims to identify the molecular mechanisms of lenvatinib in HCC. METHODS: Gene expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Wenliang, Zhang, Kelin, Chen, Xinming, Yang, Lei, Zhu, Sicong, Wei, Yingcheng, Xie, Zhiqin, Chen, Yajin, Shang, Changzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936410/
https://www.ncbi.nlm.nih.gov/pubmed/36725188
http://dx.doi.org/10.1016/j.jare.2022.03.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936410/
https://www.ncbi.nlm.nih.gov/pubmed/36725188
http://dx.doi.org/10.1016/j.jare.2022.03.012

Ejemplares similares